Nanoformulated Antiretroviral Therapy Attenuates Brain Metabolic Oxidative Stress

J. Rafael Montenegro-Burke, Christopher J. Woldstad, Mingliang Fang, Aditya N. Bade, JoEllyn M McMillan, Benson J Edagwa, Michael D. Boska, Howard Eliot Gendelman, Gary Siuzdak

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Antiretroviral therapy (ART) restricts human immunodeficiency virus type one (HIV-1) replication and by so doing, improves the quality and longevity of life for infected people. Nonetheless, treatment can also lead to adverse clinical outcomes such as drug resistance and systemic adverse events. Both could be affected by long-acting slow effective release ART. Indeed, maintenance of sustained plasma drug levels, for weeks or months, after a single high-level dosing, could improve regimen adherence but, at the same time, affect systemic toxicities. Of these, the most troubling are those that affect the central nervous system (CNS). To address this, dolutegravir (Tivicay, DTG), a potent and durable HIV integrase inhibitor used effectively in combination ART was tested. Rodents were administered parenteral 45-mg/kg doses. DTG-associated changes in CNS homeostasis were assessed by measuring brain metabolic activities. After antiretroviral treatment, brain subregions were dissected and screened by mass spectrometry-based metabolomics. Metabolic drug-related dysregulation of energy and oxidative stress were readily observed within the cerebellum and frontal cortex following native drug administrations. Each was associated with alterations in neural homeostasis and depleted canonical oxidation protection pools that included glutathione and ascorbic acid. Surprisingly, the oxidative stress-related metabolites were completely attenuated when DTG was administered as nanoformulations. These data demonstrate the importance of formulation design in control of DTG or perhaps other antiretroviral drug-associated CNS events.

Original languageEnglish (US)
Pages (from-to)2896-2907
Number of pages12
JournalMolecular Neurobiology
Volume56
Issue number4
DOIs
StatePublished - Apr 1 2019

Fingerprint

Oxidative Stress
Brain
Homeostasis
HIV Integrase Inhibitors
Central Nervous System
Pharmaceutical Preparations
Central Nervous System Agents
Metabolomics
Frontal Lobe
Drug Resistance
Cerebellum
Ascorbic Acid
Glutathione
HIV-1
Rodentia
Mass Spectrometry
Therapeutics
Maintenance
Quality of Life
HIV

Keywords

  • Antiretroviral therapy
  • Human immunodeficiency virus (HIV)
  • Metabolomics
  • Nanomedicine
  • Neuroprotection
  • Neurotoxicity

ASJC Scopus subject areas

  • Neurology
  • Cellular and Molecular Neuroscience

Cite this

Nanoformulated Antiretroviral Therapy Attenuates Brain Metabolic Oxidative Stress. / Montenegro-Burke, J. Rafael; Woldstad, Christopher J.; Fang, Mingliang; Bade, Aditya N.; McMillan, JoEllyn M; Edagwa, Benson J; Boska, Michael D.; Gendelman, Howard Eliot; Siuzdak, Gary.

In: Molecular Neurobiology, Vol. 56, No. 4, 01.04.2019, p. 2896-2907.

Research output: Contribution to journalArticle

Montenegro-Burke, J. Rafael ; Woldstad, Christopher J. ; Fang, Mingliang ; Bade, Aditya N. ; McMillan, JoEllyn M ; Edagwa, Benson J ; Boska, Michael D. ; Gendelman, Howard Eliot ; Siuzdak, Gary. / Nanoformulated Antiretroviral Therapy Attenuates Brain Metabolic Oxidative Stress. In: Molecular Neurobiology. 2019 ; Vol. 56, No. 4. pp. 2896-2907.
@article{0afad0bb191b43a6a1658287fb66f38d,
title = "Nanoformulated Antiretroviral Therapy Attenuates Brain Metabolic Oxidative Stress",
abstract = "Antiretroviral therapy (ART) restricts human immunodeficiency virus type one (HIV-1) replication and by so doing, improves the quality and longevity of life for infected people. Nonetheless, treatment can also lead to adverse clinical outcomes such as drug resistance and systemic adverse events. Both could be affected by long-acting slow effective release ART. Indeed, maintenance of sustained plasma drug levels, for weeks or months, after a single high-level dosing, could improve regimen adherence but, at the same time, affect systemic toxicities. Of these, the most troubling are those that affect the central nervous system (CNS). To address this, dolutegravir (Tivicay, DTG), a potent and durable HIV integrase inhibitor used effectively in combination ART was tested. Rodents were administered parenteral 45-mg/kg doses. DTG-associated changes in CNS homeostasis were assessed by measuring brain metabolic activities. After antiretroviral treatment, brain subregions were dissected and screened by mass spectrometry-based metabolomics. Metabolic drug-related dysregulation of energy and oxidative stress were readily observed within the cerebellum and frontal cortex following native drug administrations. Each was associated with alterations in neural homeostasis and depleted canonical oxidation protection pools that included glutathione and ascorbic acid. Surprisingly, the oxidative stress-related metabolites were completely attenuated when DTG was administered as nanoformulations. These data demonstrate the importance of formulation design in control of DTG or perhaps other antiretroviral drug-associated CNS events.",
keywords = "Antiretroviral therapy, Human immunodeficiency virus (HIV), Metabolomics, Nanomedicine, Neuroprotection, Neurotoxicity",
author = "Montenegro-Burke, {J. Rafael} and Woldstad, {Christopher J.} and Mingliang Fang and Bade, {Aditya N.} and McMillan, {JoEllyn M} and Edagwa, {Benson J} and Boska, {Michael D.} and Gendelman, {Howard Eliot} and Gary Siuzdak",
year = "2019",
month = "4",
day = "1",
doi = "10.1007/s12035-018-1273-8",
language = "English (US)",
volume = "56",
pages = "2896--2907",
journal = "Molecular Neurobiology",
issn = "0893-7648",
publisher = "Humana Press",
number = "4",

}

TY - JOUR

T1 - Nanoformulated Antiretroviral Therapy Attenuates Brain Metabolic Oxidative Stress

AU - Montenegro-Burke, J. Rafael

AU - Woldstad, Christopher J.

AU - Fang, Mingliang

AU - Bade, Aditya N.

AU - McMillan, JoEllyn M

AU - Edagwa, Benson J

AU - Boska, Michael D.

AU - Gendelman, Howard Eliot

AU - Siuzdak, Gary

PY - 2019/4/1

Y1 - 2019/4/1

N2 - Antiretroviral therapy (ART) restricts human immunodeficiency virus type one (HIV-1) replication and by so doing, improves the quality and longevity of life for infected people. Nonetheless, treatment can also lead to adverse clinical outcomes such as drug resistance and systemic adverse events. Both could be affected by long-acting slow effective release ART. Indeed, maintenance of sustained plasma drug levels, for weeks or months, after a single high-level dosing, could improve regimen adherence but, at the same time, affect systemic toxicities. Of these, the most troubling are those that affect the central nervous system (CNS). To address this, dolutegravir (Tivicay, DTG), a potent and durable HIV integrase inhibitor used effectively in combination ART was tested. Rodents were administered parenteral 45-mg/kg doses. DTG-associated changes in CNS homeostasis were assessed by measuring brain metabolic activities. After antiretroviral treatment, brain subregions were dissected and screened by mass spectrometry-based metabolomics. Metabolic drug-related dysregulation of energy and oxidative stress were readily observed within the cerebellum and frontal cortex following native drug administrations. Each was associated with alterations in neural homeostasis and depleted canonical oxidation protection pools that included glutathione and ascorbic acid. Surprisingly, the oxidative stress-related metabolites were completely attenuated when DTG was administered as nanoformulations. These data demonstrate the importance of formulation design in control of DTG or perhaps other antiretroviral drug-associated CNS events.

AB - Antiretroviral therapy (ART) restricts human immunodeficiency virus type one (HIV-1) replication and by so doing, improves the quality and longevity of life for infected people. Nonetheless, treatment can also lead to adverse clinical outcomes such as drug resistance and systemic adverse events. Both could be affected by long-acting slow effective release ART. Indeed, maintenance of sustained plasma drug levels, for weeks or months, after a single high-level dosing, could improve regimen adherence but, at the same time, affect systemic toxicities. Of these, the most troubling are those that affect the central nervous system (CNS). To address this, dolutegravir (Tivicay, DTG), a potent and durable HIV integrase inhibitor used effectively in combination ART was tested. Rodents were administered parenteral 45-mg/kg doses. DTG-associated changes in CNS homeostasis were assessed by measuring brain metabolic activities. After antiretroviral treatment, brain subregions were dissected and screened by mass spectrometry-based metabolomics. Metabolic drug-related dysregulation of energy and oxidative stress were readily observed within the cerebellum and frontal cortex following native drug administrations. Each was associated with alterations in neural homeostasis and depleted canonical oxidation protection pools that included glutathione and ascorbic acid. Surprisingly, the oxidative stress-related metabolites were completely attenuated when DTG was administered as nanoformulations. These data demonstrate the importance of formulation design in control of DTG or perhaps other antiretroviral drug-associated CNS events.

KW - Antiretroviral therapy

KW - Human immunodeficiency virus (HIV)

KW - Metabolomics

KW - Nanomedicine

KW - Neuroprotection

KW - Neurotoxicity

UR - http://www.scopus.com/inward/record.url?scp=85051457253&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051457253&partnerID=8YFLogxK

U2 - 10.1007/s12035-018-1273-8

DO - 10.1007/s12035-018-1273-8

M3 - Article

C2 - 30069830

AN - SCOPUS:85051457253

VL - 56

SP - 2896

EP - 2907

JO - Molecular Neurobiology

JF - Molecular Neurobiology

SN - 0893-7648

IS - 4

ER -